Redeye comments on Spago’s Q1 2023 report, and we judge the coming 2-3 months will provide some interesting news flows. We expect first data from the company’s phase IIa trial SpagoPix-02, and the start of the clinical phase I/IIa trial Tumorad-01. Clinical trial success with SpagoPix-02 will likely bring short- to medium-term upside to the current share price. We make adjustments to our estimates and valuation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/